Oliver Sartor

Oliver Sartor has been a central figure in the clinical development of radioligand therapy for prostate cancer, serving as lead investigator for pivotal trials that established Lu-177 PSMA-617 (Pluvicto) and radium-223 as standard-of-care treatments. His work on the VISION trial demonstrated that Lu-177 PSMA-617 significantly extends overall survival and radiographic progression-free survival in PSMA-positive metastatic castration-resistant prostate cancer, leading to FDA approval. He has advanced the theranostic paradigm in which PSMA PET imaging selects patients for PSMA-targeted radioligand therapy. His clinical research on sequencing and combining radioligand therapies with androgen receptor pathway inhibitors and immunotherapy is defining optimal treatment strategies.